Thought Leadership

Latest Report

Pharma’s Biggest Spenders 2022 Infographic

As several of the big 11 pharma companies dialled back on acquisitions, the collective bill for M&A and R&D activities among this cohort took a dip for the second consecutive year in 2022, even as Pfizer marched on with its spending spree. Their collective expenditure – $157 billion – might be the smallest since 2018, but it's still a…

Report library

Thumbnail

PD(L)anner – September 2022

Once again, Evaluate Vantage provides the latest insights and expert perspectives on new developments in the PD-(L)1 inhibitor landscape. The last few months have been…

Thumbnail

Medtech - Going steady

The medtech sector, like the wider pharma market, has been having a tough time. There are, however, glimmers of light and some interesting developments – including…

Thumbnail

Vantage Top 10 Most Read Report

The Evaluate Vantage team has rounded up our Top 10 Most-Read stories. Get up to speed on the big issues that have captured the interest and attention of your peers and…

Thumbnail

Asco 2022 eBook

Thousands of abstracts were submitted for the recent Asco meeting in Chicago and 40,000 oncology professionals gathered to delve into cutting-edge research,…